Posted on 1/7/19
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Bristol-Myers Squibb (NYSE:BMY) is acquiring Celgene (NASDAQ:CELG) for roughly $74 billion to create a biopharma goliath. The combined company will boast eight billion-dollar blockbuster drugs and . . .
Posted on 1/7/19
Should Celgene Investors Take Bristol's Money and Run?
In 2018, Bristol-Myers Squibb (NYSE:BMY) relied on just two products to drive growth, and the pharma giant's late-stage development pipeline looks like Old Mother Hubbard's cupboards. . . .
Posted on 1/7/19
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
2019 has started off with a bang in the biopharmaceutical industry. On Thursday, Bristol-Myers Squibb (NYSE:BMY) announced that it planned to acquire Celgene (NASDAQ:CELG) in a . . .
Posted on 1/5/19
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2019, . . .
Posted on 1/4/19
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an . . .
Posted on 1/4/19
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, . . .
Posted on 1/4/19
C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche
WATERTOWN, Mass.--(BUSINESS WIRE)--C4 Therapeutics (C4T) announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted . . .
Posted on 1/4/19
KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease . . .
Posted on 1/4/19
Tarveda Therapeutics Provides Year-End Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the . . .
Posted on 1/4/19
X-Chem and Vertex Expand Existing Partnership
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation of novel small molecule . . .
Posted on 1/4/19
Biogen and C4 Therapeutics Enter into Strategic Collaboration
CAMBRIDGE, Mass. and WATERTOWN, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and C4 Therapeutics (C4T) announced today that they have entered into . . .
Posted on 1/4/19
Biogen and Skyhawk Therapeutics Announce Agreement
CAMBRIDGE, Mass. and WALTHAM, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in . . .
Posted on 1/4/19
Bristol-Myers: Analysis On Celgene Deal
SummaryBristol-Myers announced a $90-billion deal for Celgene, roughly equal to its own valuation.The deal is not really welcomed by investors, which shun mega-merger deals between pharma . . .
Posted on 1/4/19
Here’s What Celgene Shareholders Are Getting From Bristol-Myers Squibb
The opportunity to secure potential best-selling drugs before they win FDA approval convinced pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) to acquire biotechnology giant Celgene (NASDAQ:CELG) on Jan. . . .
Posted on 1/4/19
Mercy Health Network Partners with PatientPing
PatientPing, a health technology company that connects providers to seamlessly coordinate patient care, today announced its launch in the state of Iowa through its partnership with . . .
Posted on 1/4/19
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical
Norwood, MA, and Tokyo, Japan, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced today that they have entered into a strategic . . .
Posted on 1/4/19
EyePoint Pharmaceuticals Provides 2019 Commercial Update
WATERTOWN, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today provided . . .
Posted on 1/8/19
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib
- Rebastinib is a Potent and Selective Inhibitor of the TIE2 kinase, the Receptor for Angiopoietins, an Important Family of Vascular Growth Factors Involved in Tumor . . .
Posted on 1/3/19
Neurable and Trimble Partner
Neurable announced that it will collaborate with Trimble (NASDAQ: TRMB) to bring brain-computer interface (BCI) technology to innovative solutions in the transportation and architecture, engineering and . . .
Posted on 1/3/19
Sojournix Completes $44 Million Series C Financing
Sojournix, a clinical stage pharmaceutical company focused on creating new medicines to transform the treatment of women's health and neuroendocrine disorders
Posted on 1/3/19
Medicinal Genomics Partners with Eiken Chemical
Medicinal Genomics Corp. (MGC), a pioneer in improving the quality, quantity and safety of cannabis, today announced it has signed a licensing agreement with Eiken Chemical . . .
Posted on 1/3/19
GENFIT and LabCorp Sign a Licensing Agreement
LILLE, France & CAMBRIDGE, Mass. & BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company, and GENFIT (Euronext: GNFT), a biopharmaceutical company focused on discovering . . .
Posted on 1/3/19
NEA Joins $31M Series A for Tiburio Therapeutics
Cydan today announced the launch of Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical
Posted on 1/3/19
Vertex and Arbor Biotechnologies Establish Collaboration
BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor) today announced that the two companies have entered into a strategic research collaboration focused . . .
Posted on 1/3/19
Nimbus Therapeutics Strengthens Leadership Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced the promotion of Holly Whittemore, C.P.A., to Chief . . .

